August 26, 2025 — Leads & Copy — Osivax, a biopharmaceutical company developing broad-spectrum protection vaccines against mutating infectious viruses, has secured $19.5 million from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). The funding will support the development of Osivax’ lead influenza A vaccine candidate, OVX836.
The multi-year agreement will fund ongoing clinical development, large-scale trial preparation, and manufacturing scale-up. An initial $11.5 million will support continued development of OVX836, with an additional $8 million for a large field efficacy study. The agreement includes potential further funding for a Phase 2b trial and CMC scale-up activities.
OVX836 targets the nucleoprotein of the influenza virus, a highly conserved internal antigen, potentially allowing for a universal approach that protects against both current and future virus strains. The vaccine candidate has been tested in 7 clinical trials with over 1,400 participants so far.
Alexandre Le Vert, CEO and Co-Founder of Osivax, said the company is excited to explore its universal flu vaccine approach and the potential of OVX836 to transform global influenza preparedness. He added that BARDA’s support is accelerating the company’s path toward late-stage development and preparing for future large-scale efficacy trials.
Alexandre LE VERT, CEO, contact@osivax.com, +33 (0)9 70 30 13 80
Source: Osivax
